WIRB - AN OPEN-LABEL, MULTIPLE-DOSE, CROSS-OVER STUDY TO EVALUATE: HIV

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 主要目的是确定奈韦拉平XR稳态时的药代动力学特征 在e3至18岁的儿童中。坚持是一个主要因素，在确定的程度 抗逆转录病毒治疗后的病毒抑制。延长释放 相对于市售制剂，奈韦拉平制剂可提供有意义的治疗获益。 奈韦拉平口服混悬剂和200 mg BID片剂，通过促进每日一次给药方案， 从而改善治疗依从性。此外，奈韦拉平缓释剂可 与市售混悬剂相比，显示出耐受性改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to establish the pharmacokinetic profile at steady state of nevirapine XR in children from e3 to 18 years of age. Adherence is a major factor in determining the degree of viral suppression achieved in response to antiretroviral therapy. An extended release formulation of nevirapine may offer a meaningful therapeutic benefit, relative to marketed nevirapine oral suspension and 200 mg BID tablets by facilitating a once daily dosing regimen, thus improving treatment compliance. In addition, nevirapine extended release could demonstrate improved tolerability in comparison with the marketed suspension.